Spinal Modulation

Spinal Modulation, Inc., a California-based medical device company, is pioneering a new era in pain management, offering targeted relief through advanced neuromodulation therapy. As per the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain affects 10 to 13% of the adult population, placing a substantial burden on the healthcare system due to limited treatment options. The company's flagship product, the Spinal Modulation Axium Neurostimulator System, is an advanced intraspinal neuromodulation therapy designed to stimulate the dorsal root ganglion (DRG) for effective pain management. This innovative system has shown success in treating chronic intractable leg pain, as well as challenging pain areas such as the back and foot. One of the key advantages of this therapy is its ability to target the DRG, allowing for fine-tuning to address broad or specific pain regions in the torso and legs, while minimizing the uncomfortable postural effects often associated with other spinal cord stimulators. Spinal Modulation secured a $45.00M Series E investment from St. Jude Medical on 07 June 2013. This funding reflects investor confidence in the company's potential to address an unmet need in the field of pain management. With its innovative approach and demonstrated success, Spinal Modulation is well-positioned to make a meaningful impact in the health care and medical devices industries.